Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Immunotherapy

• Publication date

  2013-11-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/imt.13.126PMID 24188672
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The mannose receptor

  2012cited by this paper
• Targeting tumor antigens to dendritic cells using particulate carriers.

  2012cited by this paper
• LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

  2012cited by this paper
• Decisions about dendritic cells: past, present, and future.

  2012cited by this paper
• Clinical evaluation of TRICOM vector therapeutic cancer vaccines.

  2012cited by this paper
• A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer

  2012cited by this paper
• Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

  2011cited by this paper
• MUC1 immunotherapy.

  2010cited by this paper
• Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer

  2008cited by this paper
• Strategies used for MUC1 immunotherapy: human clinical studies

  2008cited by this paper
• Mannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma

  2006cited by this paper
• Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]

  2006cited by this paper
• Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells

  2006cited by this paper
• Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer

  2005cited by this paper
• Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection.

  2001cited by this paper
• Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection

  2001cited by this paper
• MUC1, The Renaissance Molecule

  2001cited by this paper
• Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

  2000cited by this paper
• Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.

  1997cited by this paper
• Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

  1995cited by this paper

• Overcoming the novel glycan-lectin checkpoints in tumor microenvironments for the success of the cross-presentation-based immunotherapy.

  2025cites this paper
• Myelin Oligodendrocyte Glycoprotein (MOG)35–55 Mannan Conjugate Induces Human T-Cell Tolerance and Can Be Used as a Personalized Therapy for Multiple Sclerosis

  2024cites this paper
• A methamphetamine vaccine using short monoamine and diamine peptide linkers and poly-mannose.

  2024cites this paper
• Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy

  2024cites this paper
• A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way.

  2024cites this paper
• Polysaccharides—Naturally Occurring Immune Modulators

  2023influential citation
• Immunomodulatory glycomedicine: Introducing next generation cancer glycovaccines.

  2023cites this paper
• Prevention of Inflammation-Driven Colon Carcinogenesis in Human MUC1 Transgenic Mice by Vaccination with MUC1 DNA and Dendritic Cells

  2023cites this paper
• Immunotherapy for HER-2 positive breast cancer

  2023cites this paper
• Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer

  2022cites this paper
• Expression of Mucins in Different Entities of Salivary Gland Cancer: Highest Expression of Mucin-1 in Salivary Duct Carcinoma

  2022cites this paper
• Dynamic Imine Bonding Facilitates Mannan Release from a Nanofibrous Peptide Hydrogel.

  2022cites this paper
• Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy

  2022cites this paper
• MF59 Promoted the Combination of CpG ODN1826 and MUC1-MBP Vaccine-Induced Antitumor Activity Involved in the Enhancement of DC Maturation by Prolonging the Local Retention Time of Antigen and Down-Regulating of IL-6/STAT3

  2022cites this paper
• Maturation of circulating Ly6ChiCCR2+ monocytes by mannan-MOG induces antigen-specific tolerance and reverses autoimmune encephalomyelitis

  2022cites this paper
• Vaccination efforts for Buruli ulcer

  2022cites this paper
• Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management

  2022cites this paper
• Recent Progress on Therapeutic Vaccines for Breast Cancer

  2022cites this paper
• First‐in‐human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy

  2022cites this paper
• Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness

  2021cites this paper
• Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence

  2021cites this paper
• Myelin Peptide–Mannan Conjugate Multiple Sclerosis Vaccines: Conjugation Efficacy and Stability of Vaccine Ingredient

  2021cites this paper
• Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan

  2021cites this paper
• Strategy and clinical application of up-regulating cross presentation by DCs in anti-tumor therapy.

  2021cites this paper
• Emerging immunotherapeutic strategies for the treatment of breast cancer

  2021cites this paper
• The Crosstalk Between Dendritic Cells, Cytokine-Induced Killer Cells And Cancer Cells From The Perspective Of Combination Therapy

  2021cites this paper
• Purified mucins in drug delivery research.

  2021cites this paper
• ROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?

  2021cites this paper
• Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options.

  2021cites this paper
• Emerging glyco‐based strategies to steer immune responses

  2021cites this paper
• Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action

  2021cites this paper
• Carbohydrate Conjugates in Vaccine Developments

  2020cites this paper
• Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.

  2020cites this paper
• Plant-Derived Nutraceuticals and Immune System Modulation: An Evidence-Based Overview

  2020cites this paper
• Single peptides and combination modalities for triple negative breast cancer

  2020influential citation
• Epiphanies of well-known and newly discovered macromolecular carbohydrates - A review.

  2020cites this paper
• Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes

  2020cites this paper
• The Use of Electrochemical Voltammetric Techniques and High-Pressure Liquid Chromatography to Evaluate Conjugation Efficiency of Multiple Sclerosis Peptide-Carrier Conjugates

  2020cites this paper
• The Long Road of Immunotherapeutics against Multiple Sclerosis †

  2020cites this paper
• O-glycan recognition and function in mice and human cancers.

  2020cites this paper
• HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development

  2020cites this paper
• Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-Like Particles.

  2019cites this paper
• Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches

  2019cites this paper
• Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy.

  2019cites this paper
• Use of Dendritic Cell Receptors as Targets for Enhancing Anti-Cancer Immune Responses

  2019cites this paper
• Cripto-1: potential target for cancer immunotherapy?!

  2019cites this paper
• Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection

  2019cites this paper
• Regulation of Immunity in Breast Cancer

  2019cites this paper
• The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer

  2019cites this paper
• Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice

  2019cites this paper
• Combination Immunotherapy Strategies in Breast Cancer

  2019cites this paper
• The balance between breast cancer and the immune system: challenges for prognosis and clinical benefit from immunotherapies.

  2019cites this paper
• Breast cancer vaccines: Heeding the lessons of the past to guide a path forward.

  2019cites this paper
• Broad and thematic remodeling of the surface glycoproteome on isogenic cells transformed with driving proliferative oncogenes

  2019cites this paper
• Mannose and Mannose‐6‐Phosphate Receptor–Targeted Drug Delivery Systems and Their Application in Cancer Therapy

  2018cites this paper
• Carbohydrate-Based Adjuvants for Vaccine Production

  2018cites this paper
• Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.

  2018cites this paper
• Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer

  2018cites this paper
• Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid

  2018cites this paper
• Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope

  2018cites this paper
• MUC1 and Cancer Immunotherapy

  2018cites this paper
• Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

  2018cites this paper
• Chimeric antigen receptor (CAR) T-cell immunotherapy for MUC1-positive breast cancer

  2018cites this paper
• Latest developments in MUC1 immunotherapy

  2018cites this paper
• Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.

  2018cites this paper
• Multiple Sclerosis: Immunopathology and Treatment Update

  2017cites this paper
• Glycan Markers as Potential Immunological Targets in Circulating Tumor Cells.

  2017cites this paper
• Sugar Based Biopolymers in Nanomedicine; New Emerging Era for Cancer Imaging and Therapy.

  2017cites this paper
• Breast cancer genomics and immuno-oncological markers to guide immune therapies.

  2017cites this paper
• Mannosylated T/Tn with Freund’s adjuvant induces cellular immunity

  2017cites this paper
• Molecular Pathways: Mucins and Drug Delivery in Cancer

  2016cites this paper
• Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes

  2016cites this paper
• Engineering Stem Cells for Biomedical Applications

  2016cites this paper
• Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune Responses.

  2016cites this paper
• MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice

  2016cites this paper
• Exosomes : immunomodulators in cancer and therapy

  2016cites this paper
• Examination of Prostate Cancer Stem-like Cell Associated Factors for their Contribution Towards the Development of Castration Resistant Prostate Cancer

  2016cites this paper
• TG4010: a vaccine with a therapeutic role in cancer.

  2016cites this paper
• Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond

  2016cites this paper
• Vaccine delivery by penetratin: mechanism of antigen presentation by dendritic cells

  2016cites this paper
• Immunotherapy in Breast Cancer

  2016cites this paper
• Pre-clinical toxicity and immunogenicity evaluation of a MUC1-MBP/BCG anti-tumor vaccine.

  2016cites this paper
• Guiding principles in the design of molecular bioconjugates for vaccine applications.

  2015cites this paper
• Anti-MUC1 Antibody in Nipple Aspirate Fluids Correlates with Tumor Aggressiveness in Breast Cancer: A Feasibility Study

  2015cites this paper
• Evaluation of peptide-mediated dendritic cell targeting and particulate adjuvants for immunotherapy

  2015cites this paper
• Synthesis of a MUC1 Mucin Cyclic Dimer Peptide and Its Antibody Binding Properties as Revealed by STD-NMR

  2015cites this paper
• Peptide vaccines in breast cancer: The immunological basis for clinical response.

  2015cites this paper
• Polysaccharides: Candidates of promising vaccine adjuvants.

  2015cites this paper
• Molecular basis of antibody binding to mucin glycopeptides in lung cancer

  2015cites this paper
• Comparative Immunogenicity of a Cytotoxic T Cell Epitope Delivered by Penetratin and TAT Cell Penetrating Peptides

  2015cites this paper
• Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells.

  2015cites this paper
• Update on Mucin-1 immunotherapy in cancer: a clinical perspective

  2015cites this paper
• Immunotherapy for the Prevention and Treatment of Breast Cancer

  2015cites this paper
• Breast cancer and immunology: biomarker and therapeutic developments

  2015cites this paper
• Recent advances in the development of breast cancer vaccines

  2014cites this paper
• Sugar-Based Immune Adjuvants for Use in Recombinant, Viral Vector, DNA and Other Styles of Vaccines

  2014cites this paper
• Novel Technologies for Vaccine Development

  2014cites this paper
• Trial watch: Dendritic cell-based anticancer therapy

  2014cites this paper
• Dendritic cell immunotherapy: clinical outcomes

  2014cites this paper